Losartan versus atenolol in the Marfan aorta—how to treat?

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration

(2015) Alex Pitcher et al.   AMERICAN HEART JOURNAL

Beneficial Outcome of Losartan Therapy Depends on Type ofFBN1Mutation in Marfan SyndromeCLINICAL PERSPECTIVE

(2015) Romy Franken et al.   Circulation-Cardiovascular Genetics

Beneficial Outcome of Losartan Therapy Depends on Type ofFBN1Mutation in Marfan SyndromeCLINICAL PERSPECTIVE

(2015) Romy Franken et al.   Circulation-Cardiovascular Genetics

Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome

(2014) Ronald V. Lacro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial

(2013) M. Groenink et al.   EUROPEAN HEART JOURNAL

Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome

(2013) Romy Franken et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Losartan Added to β-Blockade Therapy for Aortic Root Dilation in Marfan Syndrome: A Randomized, Open-Label Pilot Study

(2013) Hsin-Hui Chiu et al.   MAYO CLINIC PROCEEDINGS

Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome

(2012) Alexander W Hartog et al.   EXPERT OPINION ON PHARMACOTHERAPY

Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome

(2008) Benjamin S. Brooke et al.   NEW ENGLAND JOURNAL OF MEDICINE